BRAF and neoplasm: Median follow-up was 49.4 months, 8.7% had acral cutaneous melanoma, 50% were BRAF-positive, 79.9% were LAG-3 positive, 26.1% were tumor PD-L1-positive and 6.5% received prior adjuvant therapy.